IRIS

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM) / Ascierto, P. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:8(2018). ( 43rd ESMO Congress (ESMO)) [10.1093/annonc/mdy289.060].

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)

Ascierto P
2018
2018
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM) / Ascierto, P. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:8(2018). ( 43rd ESMO Congress (ESMO)) [10.1093/annonc/mdy289.060].
4.2 Abstract in Atti di convegno
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014380
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 7
social impact